Status: Recruiting
A Study of BLB-201 RSV Vaccine in Infants and Children
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Participants needed: 137
Trial details
Phase: Phase 1, Phase 2Age: 6-5Biological sex: AllType: InterventionalSponsor: Blue Lake Biotechnology Inc.Updated: Jun 3, 2026Locations: 15
Eligibility criteria
Not listed